Targeting CD40 by agonistic mABs powerfully enhanced responses of both anti-PD1 and anti-CTLA4 therapies in an immunotherapy-resistant pancreatic cancer model (69). This evidence concerns the gene CTLA4 and pancreatic neoplasm.